Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

作者：Fanghui Zhao, Ting Wu, Yuemei Hu, Lihui Wei, Mingqiang Li, Weijin Huang, Wen Chen, Shoujie Huang, Qinjing Pan, Xun Zhang, Ying Hong, Chao Zhao, Li Q, Kai Chu, Yunfei Jiang, Mingzhu Li, Jie Tang, Caihong Li, Dongping Guo, Li-Dong Ke, Xin Wu, Xingmei Yao, Jianhui Nie, Bizhen Lin, Yuqian Zhao, Meng Guo, Jun Zhao, Feng-Zhu Zheng, Xiaoqian Xu, Yingying Su, Qiu-Fen Zhang, Guang Sun, Fengcai Zhu, Shaowei Li, Yimin Li, Huirong Pan, Jun Zhang, You‐Lin Qiao, Ningshao Xia · 发表于：The Lancet Infectious Diseases · 年份：2022 · DOI：10.1016/s1473-3099(22)00435-2 · 被引用次数：93 · 研究领域：Cervical Cancer and HPV Research、Immunotherapy and Immune Responses、Reproductive tract infections research